ClinicalTrials.gg
RecruitingNCT06077435Updated Nov 24, 2025

Comparative Analysis of AI Software for Enhanced Polyp Detection and Diagnosis

An interventional study of AI in Colonic Polyp and Colon Lesion, sponsored by Sahlgrenska University Hospital. Recruiting at 1 site in Sweden. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Sahlgrenska University Hospital · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Registered 6 months after the study started (first participant enrolled Mar 2023, registered Sep 2023).
  • Started Mar 2023; still recruiting 3 years 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
915
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Study summary

Purpose \& Research Questions

The purpose of this study is to evaluate whether artificial intelligence (AI) improves the detection of polyps and whether the system can classify the type and severity of detected changes. The investigators will also assess if there are any differences between the various AI systems and whether the polyps that may be missed are benign or malignant.

Read the detailed description

Materials: Selection, Representativeness, and Grouping

The study is a randomized controlled clinical trial conducted at Västra Götaland region. Patients are randomized to receive either AI or conventional endoscopy, and each endoscopy unit has access to at least one AI device. Informed consent is obtained from patients before the examination.

Before the examination, patients are asked if they want to participate in the study. If the patient wishes to participate, informed consent is obtained. The endoscopist then draws a slip from an envelope, determining whether conventional colonoscopy or AI will be used. During conventional colonoscopy, the patient is examined according to routine practice. After the examination, a questionnaire is filled out, recording various findings from the examination. During AI examinations, the AI system is activated only during instrument withdrawal. The system identifies polyps and alerts the endoscopist. Additionally, two of the AI systems (GI-Genius, CADEYE) have the ability to characterize the detected polyps and provide an interpretation of whether the changes are benign or malignant. After the examination, a similar questionnaire is completed as in conventional colonoscopy.

Method: Data Collection

Basic data will be recorded, including the reason for the examination, other illnesses, medications, demographic data such as gender, age, family history of cancer, and the time of the examination (morning or afternoon). During the examination, the following will be recorded: the number of polyps, macroscopic classification of polyps, AI system's characterization of the polyps, bowel cleansing quality, laxative method, medication during the examination, complications occurring during or after the examination. Withdrawal time is recorded, as well as the number of false-positive polyps and supplementation with histological data of polyps after review by the pathologist. All materials and costs associated with the examination are recorded.

Three different AI systems will be used at the various hospital sites, namely EndoAid (Olympus), CADEYE (Fujinon), and GI-Genius (Medtronic). All units will randomize each examination to either AI or non-AI.

02

Conditions studied

  • Colonic Polyp
  • Colon Lesion

Browse trials for

03

In context

Colonic Polyps

377 studies on the registry are indexed under Colonic Polyps; 57 are open to participants now.

This study's planned enrollment of 915 is above the median of 274 across 250 interventional studies indexed under Colonic Polyps.

Browse Colonic Polyps studies →

Lead sponsor

Sahlgrenska University Hospital is the lead sponsor of 263 studies on the registry; 68 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 50 years
  • Elective colonoscopy

Exclusion criteria

Exclusion Criteria:

  • Patient declines to participate in the study.
  • Age \< 50 years
  • Unprepared bowel
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
915 participants (estimated)

Study arms

  • Active comparator
    CAD-EYE

    AI system 1. Sealed envelopes in blocks of four were used for randomisation.

    Device: AI

  • Active comparator
    GI-GENIUS

    AI system 2. Sealed envelopes in blocks of four were used for randomisation

    Device: AI

  • Active comparator
    Endo-AID

    AI system 3. Sealed envelopes in blocks of four were used for randomisation

    Device: AI

  • No intervention
    No AI

    No AI. conventional examination. Sealed envelopes in blocks of four were used for randomisation

Interventions

  • DeviceAI

    AI system

06

What researchers measure

Primary outcomes

  1. To compare the effectiveness of AI systems in characterizing polyps with conventional histology

    The endoscopist's ability to characterize lesions with and without AI will be assessed, and this assessment will be compared to histology

    Time frame: During procedure (5minutes)

  2. Comparison of Adenoma Detection Rates (ADR) between colonoscopies assisted by Artificial Intelligence (AI) and conventional colonoscopies without AI

    The ADR is typically expressed as a percentage and is calculated using the following formula:Number of colonoscopies with adenoma detection/ Total number of colonoscopies ×100.

    Time frame: During procedure (up to 40 minutes)

  3. To assess and compare the costs associated with AI-assisted colonoscopy versus conventional colonoscopy.

    Each cost associated with each examination, whether using AI-assisted or conventional colonoscopy, will be recorded prospectively.

    Time frame: During procedure (5minutes)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Mar 2026, 36 months after the start.

Of 132 non-industry interventional studies with no phase under Colonic Polyps, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's planned 36 months is above that.

Counting every sponsor, half of 149 studies reached it within 17 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2023
First posted
Oct 11, 2023
StartActual
Mar 1, 2023
Primary completionEst.
Mar 1, 2026
CompletionEst.
Jun 1, 2026
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06077435
Responsible party
Jonas Varkey (Principal investigator, Senior Consultant, MD, PhD,, Sahlgrenska University Hospital) — Principal investigator
First posted
Oct 11, 2023
Start date
Mar 1, 2023
Primary completion
Mar 1, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Nov 24, 2025

Study contacts

Jonas Varkey, MD, PhD
Contact
jonas.varkey@vgregion.se
0046764030388
Per Hedenstrom, MD. Ph D
study director · Sahlgrenska University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion